← Back
Data updated: Mar 10, 2026
NASPRESS
Pharmaceuticals
NASPRESS is a generic drug manufacturer with 1 FDA-approved products.
2025
Since
1
Drugs
-
Trials
11
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
MOMETASONE FUROATE 2025-12-10
Labeling
MOMETASONE FUROATE 2025-05-15
MOMETASONE FUROATE 2024-11-27
Labeling
MOMETASONE FUROATE 2024-11-27
Labeling
MOMETASONE FUROATE 2024-11-27
Labeling
MOMETASONE FUROATE 2024-11-27
Labeling
MOMETASONE FUROATE 2024-11-22
MOMETASONE FUROATE 2024-08-14
Labeling
MOMETASONE FUROATE 2024-08-14
Labeling
MOMETASONE FUROATE 2024-04-23
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
No indication data
Pipeline Strength Pro
Loading...
Active (0)
Discontinued (1)
Company Info
- First Approval
- 2025-05-15
- Latest
- 2025-05-15
- Applications
- 1